Oscient's third-quarter revenues double from prior-year period to $12.4 million

By Lisa Kerner

Charlotte, N.C., Nov. 9 - Oscient Pharmaceuticals Corp. said its total revenue for the three months ended Sept. 30 more than doubled to $12.4 million from $5.9 million for the three months ended Sept. 30, 2005.

Third-quarter 2006 revenues included $4.3 million from Antara (fenofibrate) capsules and $4.0 million in revenues related to Factive (gemifloxacin mesylate) tablets.

"The $4.3 million in Antara revenues represent approximately six weeks of sales," president and chief executive officer Steven M. Rauscher said in a company news release.

Oscient also accomplished several important milestones related to Factive during the quarter, including the sublicense of Factive rights to Abbott Canada, officials said. In addition, Pfizer Mexico received approval for three indications and launched Factive in Mexico.

The company had a reported net loss for the third quarter of $20.7 million, or $0.20 per share, compared with a net loss of $21.9 million, or $0.29 per share, for the prior-year period.

Selling, marketing, general and administrative expenses were down slightly in the quarter at $21.6 million from $22.0 million in the third-quarter 2005.

For the nine months ended Sept. 30, Oscient recorded total revenue of $27.9 million and a net loss of $63.8 million, or $0.70 per share.

Oscient is a commercial-stage biopharmaceutical company based in Waltham, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.